Gilead Signs an Agreement with Nurix to Develop and Commercialize Protein Degradation Therapies for Cancer and Other Disease

Gilead Signs an Agreement with Nurix to Develop and Commercialize Protein Degradation Therapies for Cancer and Other Disease

Shots:

  • Nurix to receive $45M upfront, up to $2.3B as milestones and royalties on sales, and will identify novel targets, utilizing its discovery platform & E3 ligases inducing degradation of targets. Nurix retains an option to co-develop and co-detail up to 2 programs with equal profit & loss sharing with split cost in the US, receives royalties on sales (Ex-US) & reduced milestones for opted programs
  • Gilead to get an option to license drug candidates up to 5 targets developed by Nurix and get rights to develop & commercialize targeted protein degradation drugs for patients with cancer and other challenging diseases
  • Nurix’s technology platform focuses on the manipulation of the ubiquitin system and its component E3 ligases, responsible for controlling protein levels in human cells

Click here to read full press release/ article | Ref: Gilead | Image: Touch Creative